|
« back to client info
 For more information please contact:
Kevin McGrath
212.245.4577
Kevin@cameronassoc.com |
QuickLinks:
Press Releases »
Client Website »
Stock Quote »
Client Calendar »
|
|
December 20, 2011
DARA BioSciences Reports Appointment of Steve Gorlin as a Director and Designation of David J. Drutz as President and Chief Executive Officer
- downloadp pdf (32 kb) »
|
December 7, 2011
DARA BioSciences Reports Management Changes
- download pdf (27 kb) »
|
November 2, 2011
Selected to Present at Conferences
- download pdf (33 kb) »
|
November 1, 2011
Announces Positive Results From a Successfully Completed Phase 1b Clinical Study
- download pdf (38 kb) »
|
October 10, 2011
KRN5500 Demonstrated Significant Decrease in the Intensity of Neuropathic Pain in Patients with Cancer According to Findings Published in the Journal of Pain and Symptom Management
- download pdf (113 kb) »
|
September 6, 2011
DARA BioSciences to Present at Rodman & Renshaw Annual Global Healthcare Investment Conference
- download pdf (32 kb) »
|
August 18, 2011
DARA BioSciences Receives Designation from U.S. FDA for KRN5500 - Treatment of Chemotherapy-Induced Neuropathic Pain in Caner Patients
- download pdf (72 kb) »
|
May 3, 2011
NHS National Innovation Centre Identifies Celution(R) as Cost-Effective Innovative Technology for Partial Breast Reconstruction
- download pdf (24 kb) »
|
November 2, 2010:
DARA BioSciences Awarded Grants Totaling Approximately $500,000 for Its Two Drugs Advancing Through Clinical Studies
- download word.doc (40 Kb) »
|
October 25, 2010:
DARA BioSciences Signs Definitive Agreement to Raise $1.4 Million in Registered Direct Offering
- download word.doc (40 Kb) »
|
September 8, 2010:
DARA Announces Analytical Results in Efficacy and Dose Response of KRN5500 in Patients with Chemotherapy Induced Peripheral Neuropathy and Advanced Cancer
- download word.doc (40 Kb) »
|
July 1, 2010:
DARABiosciences, Inc. Announces it is Indefinitely Suspending its Public Unit Offering
- download word.doc (40 Kb) »
|
June 28, 2010:
DARA BioSciences Reports on SurgiVision Receiving FDA Clearance to Market Its ClearPoint System
- download word.doc (40 Kb) »
|
April 27, 2010:
DARA BioSciences Enters Into a Clinical Trial Collaboration With the Division of Cancer Prevention (DCP), National Cancer Institute (NCI) for the Clinical Development of KRN5500
- download word.doc (40 Kb) »
|
April 20, 2010:
DARA BioSciences to Present Results of a Phase 2 Clinical Study for KRN5500 at the "Third International Congress on Neuropathic Pain"
- download word.doc (40 Kb) »
|
March 25, 2010:
DARA BioSciences Initiates a Phase I Clinical Study of DB959 for the Treatment of Type 2 Diabetes
- download word.doc (40 Kb) »
|
March 19, 2010:
DARA Receives Anticipated Notice of Non-Compliance From NASDAQ
- download word.doc (40 Kb) »
|
March 1, 2010:
DARA BioSciences Closes at Market Private Placement Transaction
- download word.doc (40 Kb) »
|
December 23, 2009:
DARA BioSciences Reports on SurgiVision's Filing of a Registration Statement With the Securities and Exchange Commission for an Initial Public Offering (IPO)
- download word.doc (40 Kb) »
|
November 23, 2009:
DARA BioSciences Presented Results of Its Phase 2 Study for KRN5500 at the "12th International Conference on the Mechanisms and Treatment of Neuropathic Pain"
- download word.doc (40 Kb) »
|
November 4, 2009:
DARA BioSciences Secures Additional Intellectual Property Relating to Spicamycin
- download word.doc (40 Kb) »
|
October 22, 2009:
DARA BioSciences Regains NASDAQ Compliance
- download word.doc (40 Kb) »
|
October 13, 2009:
DARA BioSciences Signs Definitive Agreement to Raise Approximately $750,000 in Registered Direct Offering
- download word.doc (40 Kb) »
|
October 12, 2009:
DARA BioSciences and America Stem Cell Broaden Collaboration
- download word.doc (40 Kb) »
|
September 18, 2009:
DARA BioSciences Signs Definitive Agreement to Raise $1.2155 Million in Registered Direct Offering
- download word.doc (40 Kb) »
|
September 17, 2009:
DARA BioSciences Announces Receipt of NASDAQ Letter Citing Non-Compliance with Minimum Bid Price Rules
- download word.doc (40 Kb) »
|
September 15, 2009:
DARA BioSciences Will Present Phase 2a Study Results for KRN5500 at the 12th International Conference on the Mechanisms and Treatment of Neuropathic Pain Meeting
- download word.doc (40 Kb) »
|
September 11, 2009:
Dara Biosciences Signs Definitive Agreement To Raise $2.5 Million In Registered Direct Offering
- download word.doc (40 Kb) »
|
